Celltrion to cancel 1.7 trillion won in treasury shares to boost shareholder value
Celltrion, a major Korean biopharmaceutical company, said Wednesday it will cancel 1.7 trillion won ($1.1 billion) worth of treasury shares this month as part of efforts to enhance shareholder value.
